CTNI-72. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Current standard-of-care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ. Almost all GBM patients experience recurrent/progressive disease despite upfront standard of care treatment, with a median survival after re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: O’Brien, Barbara, Penas-Prado, Marta, Kamiya-Matsuoka, Carlos, Weathers, Shiao-Pei, Yung, W K Alfred, Loghin, Monica, Harrison, Rebecca, Majd, Nazanin, Bacha, Jeffrey, Brown, Dennis, Johnson, Greg, Langlands, John, Schwartz, Richard, Kanekal, Sarath, Steino, Anne, Lopez, Lorena, de Groot, John
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Clinical Trials: Non-Immunologic
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651480/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.238
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares